Shi Yang | Medicine and Dentistry | Best Researcher Award

Prof. Shi Yang | Medicine and Dentistry | Best Researcher Award

Prof. Shi Yang Boston |  University Medical Center | United States

Dr. Shi Yang is a Clinical Professor in the Department of Pathology and Laboratory Medicine at Boston University Chobanian & Avedisian School of Medicine and Director of the Diagnostic Molecular Pathology Laboratory at Boston Medical Center. He earned his MB from Hebei Medical College in China and his MMSc in Pathology from the Chinese Academy of Medical Sciences. With decades of academic and research leadership in molecular diagnostics and cancer pathology, he has become a recognized expert in colorectal and melanoma molecular pathways. His multilingual, patient-centered approach reflects deep dedication to both education and translational science.

Profile

Orcid

Education

Dr. Yang completed his MB at Hebei Medical College and his Master of Medicine in Cancer Pathology at the Cancer Institute of the Chinese Academy of Medical Sciences in Beijing under the mentorship of Professor Quijie Xia. He also pursued advanced training in imaging analysis, molecular techniques, and clinical research at leading institutions in the United States, laying a strong foundation for his expertise in molecular diagnostics and academic pathology.

Experience

Dr. Yang began his career as an Assistant Professor in China before joining Boston University as a faculty member in pathology. He steadily advanced to Clinical Full Professor and Director of the Molecular Pathology Laboratory, where he leads diagnostic innovation and teaching. His career blends clinical service, academic mentorship, and administrative leadership, shaping both institutional practices and the professional growth of countless trainees and colleagues.

Research Interest

Dr. Yang’s research focuses on molecular and epigenetic mechanisms underlying colorectal and melanoma carcinogenesis, particularly serrated polyp pathways, oncogenic mutations, and CpG island methylation. He also investigates molecular diagnostics for hematologic and solid tumors and explores dietary prevention strategies in oncology, such as the effects of green tea in breast cancer. His research bridges basic science with clinical applications, improving diagnostic accuracy and patient outcomes.

Award

Dr. Yang’s professional recognition is reflected in his leadership positions across research centers and university committees. He has been a founding member of key genomic research initiatives and has consistently been appointed to influential roles that drive advancements in molecular pathology, education, and clinical practice. His contributions have strengthened the integration of laboratory science and clinical diagnostics.

Publication Top Notes

Title: Molecular and Clinicopathological Profiling of Clear Cell Renal Cell Carcinoma with Rhabdoid Features: An Integrative Pathway-Based Stratification Approach
Journal: Cancers 
Authors: Zhichun Lu, Qing Zhao, Huihong Xu, Mark H. Katz, David S. Wang, Christopher D. Andry, Shi Yang

Title: A Polymorphism in the Lysyl Oxidase Propeptide Domain Accelerates Carcinogen-induced Cancer
Journal: Boston University Research 
Authors: Shi Yang and collaborators

Title: Tumoral PD-L1 Expression in Desmoplastic Melanoma is Associated with Depth of Invasion, Tumor-Infiltrating CD8 Cytotoxic Lymphocytes and the Mixed Cytomorphological Variant
Journal: Modern Pathology 
Authors: Shi Yang and collaborators

Title: BRAF and Epithelial-Mesenchymal Transition in Primary Cutaneous Melanoma: A Role for Snail and E-cadherin?
Journal: Human Pathology 
Authors: Shi Yang and collaborators

Title: Telomerase (TERT) Promoter Mutations are Infrequent in Merkel Cell Carcinomas
Journal: Journal of the American Academy of Dermatology 
Authors: Shi Yang and collaborators

Conclusion

Dr. Shi Yang is a distinguished pathologist whose expertise in molecular diagnostics and education has made lasting contributions to the field. His commitment to research, patient care, and mentorship demonstrates a unique ability to bridge scientific innovation and clinical application. Through his leadership and scholarly output, he continues to influence pathology practice and academic training globally.